Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Drops By 19.4%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 92,700 shares, a decline of 19.4% from the March 15th total of 115,000 shares. Based on an average daily volume of 107,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SABS. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a report on Tuesday, April 1st. Chardan Capital decreased their price target on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $11.40.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Silver Oak Securities Incorporated purchased a new position in SAB Biotherapeutics in the first quarter worth approximately $30,000. Northern Trust Corp purchased a new position in SAB Biotherapeutics in the fourth quarter valued at $43,000. Diadema Partners LP acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at $114,000. Geode Capital Management LLC lifted its holdings in SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares during the last quarter. Finally, HB Wealth Management LLC lifted its holdings in SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after buying an additional 128,800 shares during the last quarter. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 0.6 %

Shares of SABS traded down $0.01 during mid-day trading on Monday, hitting $1.43. 53,700 shares of the company’s stock were exchanged, compared to its average volume of 61,593. The stock’s 50-day moving average is $1.54 and its 200-day moving average is $2.66. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.01. The company has a market cap of $13.25 million, a price-to-earnings ratio of -0.39 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.12 million. On average, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.